The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
Open accessAbstract
We demonstrate that phosphatidylinositol 3-kinase (PI3K) pathway aberrations occur in >80% of endometrioid endometrial cancers, with coordinate mutations of multiple PI3K pathway members being more common than predicted by chance. PIK3R1 (p85α) mutations occur at a higher rate in endometrial cancer than in any other tumor lineage, and PIK3R2 (p85β), not previously demonstrated to be a cancer gene, is also frequently mutated. The dominant activation event in the PI3K pathway appears to be PTEN protein loss. However, in tumors with retained PTEN protein, PI3K pathway mutations phenocopy PTEN loss, resulting in pathway activation. KRAS mutations are common in endometrioid tumors activating independent events from PI3K pathway aberrations. Multiple PIK3R1 and PIK3R2 mutations demonstrate gain of function, including disruption of a novel mechanism of pathway regulation wherein p85α dimers bind and stabilize PTEN. Taken together, the PI3K pathway represents a critical driver of endometrial cancer pathogenesis and a novel therapeutic target. Significance: Our data indicate that the PI3K pathway is targeted in the vast majority of endometrioid endometrial cancers leading to PI3K pathway activation. Frequent oncogenic mutations in PIK3R1 and PIK3R2 provide evidence for their role in endometrial cancer pathophysiology with patient-specific mutations revealing a novel mechanism by which p85α regulates the PI3K pathway through stabilizing PTEN. Cancer Discovery; 1(2); 170–85. ©2011 AACR. Read the Commentary on this article by Herrero-Gonzalez and Di Cristofano, p. 106 This article is highlighted in the In This Issue feature, p. 91
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ueki, K., Fruman, D. A., Yballe, C. M., Fasshauer, M., Klein, J., Asano, T., Cantley, L. C., & Kahn, C. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305602200 · Cited by 208
Self-citationRetractedComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“In the COSMIC database (30), PIK3R1 mutations were detected in 36 of 1693 (2%) tumors.”
BackgroundExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Self-citationEngelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Self-citationThe PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Self-citationTenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
Phosphorylation of the PTEN Tail Regulates Protein Stability and Function
Vazquez, F., Ramaswamy, S., Nakamura, N., & Sellers, W. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5010-5018.2000 · Cited by 774
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Vazquez, F., Grossman, S. R., Takahashi, Y., Rokas, M. V., Nakamura, N., & Sellers, W. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100556200 · Cited by 413
Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D., & Yan, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1170 · Cited by 337
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression
Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., & Ittmann, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201167798 · Cited by 323
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Chaudhuri, S., Stern, H. M., Wang, W., Kan, Z., Dbouk, H. A., Peters, B. A., Waring, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.016 · Cited by 289
Ueki, K., Fruman, D. A., Brachmann, S. M., Tseng, Y.-H., Cantley, L. C., & Kahn, C. R. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.3.965-977.2002 · Cited by 285
Self-citationIhle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 274
Self-citationSlomovitz, B. M., Lu, K. H., Johnston, T., Coleman, R. L., Munsell, M., Broaddus, R. R., Walker, C., Ramondetta, L. M., Burke, T. W., Gershenson, D. M., et al. (2010) · Cancer · doi:10.1002/cncr.25515 · Cited by 269
Self-citationO'Brien, C., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 255
Abnormalities of the APC/β-catenin pathway in endometrial cancer
Moreno-Bueno, G., Hardisson, D., Sánchez, C., Sarrió, D., Cassia, R., García-Rostán, G., Prat, J., Guo, M., Herman, J. G., Matías-Guiu, X., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205924 · Cited by 237
Conditional Loss of Uterine Pten Unfailingly and Rapidly Induces Endometrial Cancer in Mice
Daikoku, T., Hirota, Y., Tranguch, S., Joshi, A. R., DeMayo, F. J., Lydon, J. P., Ellenson, L. H., & Dey, S. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1274 · Cited by 225
A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas
Rudd, M. L., Price, J. C., Fogoros, S., Godwin, A. K., Sgroi, D. C., Merino, M. J., & Bell, D. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0540 · Cited by 222
Molecular identification of latent precancers in histologically normal endometrium.
Mutter, G. L., Ince, T. A., Baak, J. P. A., Kust, G. A., Zhou, X. P., & Eng, C. (2001) · PubMed · Cited by 204
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase
Chagpar, R. B., Links, P. H., Pastor, M. C., Furber, L. A., Hawrysh, A. D., Chamberlain, M. D., & Anderson, D. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908899107 · Cited by 194
Oda, K., Okada, J., Timmerman, L., Rodriguez-Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z. A., Shokat, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0755 · Cited by 189
Taniguchi, C. M., Winnay, J., Kondo, T., Bronson, R. T., Guimaraes, A. R., Alemán, J. O., Luo, J., Stephanopoulos, G., Weissleder, R., Cantley, L. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3399 · Cited by 166
Self-citationCorrelation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Kanamori, Y., Kigawa, J., Itamochi, H., Shimada, M., Takahashi, M., Kamazawa, S., Sato, S., Akeshima, R., & Terakawa, N. (2001) · PubMed · Cited by 165
PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations☆
Velasco, A., Bussaglia, E., Pallarés, J., Dolcet, X., Llobet‐Navàs, D., Encinas, M., Llecha, N., PALACIOS, J., Prat, J., & Matías‐Guiu, X. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.05.007 · Cited by 160
Sun, M., Hillmann, P., Hofmann, B. T., Hart, J. R., & Vogt, P. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009652107 · Cited by 155
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
Shoji, K., Oda, K., Nakagawa, S., Murayama-Hosokawa, S., Nagae, G., Uehara, Y., Sone, K., Miyamoto, Y., Hiraike, H., Hiraike-Wada, O., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605109 · Cited by 154
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas
Murugan, A. K., Hồng, N. T., Fukui, Y., Munirajan, A. K., & Tsuchida, N. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.1.101 · Cited by 146
Mutational Analysis of the PTEN Gene in Endometrial Carcinoma and Hyperplasia
Sun, H., Enomoto, T., Fujita, M., Wada, H., Yoshino, K., Ozaki, K., Nakamura, T., & Murata, Y. (2001) · American Journal of Clinical Pathology · doi:10.1309/7jx6-b9u9-3p0r-eqny · Cited by 104
Wu, H., Shekar, S. C., Flinn, R. J., El‐Sibai, M., Jaiswal, B. S., Sen, K. I., Janakiraman, V., Seshagiri, S., Gerfen, G. J., Girvin, M. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902369106 · Cited by 95
p85 Associates with Unphosphorylated PTEN and the PTEN-Associated Complex
Rabinovsky, R., Pochanard, P., McNear, C. J., Brachmann, S. M., Duke‐Cohan, J. S., Garraway, L. A., & Sellers, W. R. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01649-08 · Cited by 92
Input from Ras is required for maximal PI(3)K signalling in Drosophila
Orme, M. H., Alrubaie, S., Bradley, G. L., Walker, C. D., & Leevers, S. J. (2006) · Nature Cell Biology · doi:10.1038/ncb1493 · Cited by 85
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma
Hayes, M. P., Douglas, W., & Ellenson, L. H. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.12.021 · Cited by 76
DNA Mismatch Repair Deficiency in Endometrial Carcinoma
Karamurzin, Y. S., & Rutgers, J. K. L. (2009) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31818d8fe6 · Cited by 71
Jarboe, E. A., Pizer, E. S., Miron, A., Monte, N., Mutter, G. L., & Crum, C. P. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.197 · Cited by 68
Hsu, J.-H., Shi, Y., Frost, P., Yan, H., Hoang, B. Q., Sharma, S., Gera, J., & Lichtenstein, A. K. (2004) · Oncogene · doi:10.1038/sj.onc.1207459 · Cited by 62
Serial dilution curve: a new method for analysis of reverse phase protein array data
Zhang, L., Wei, Q., Mao, L., Liu, W., Mills, G. B., & Coombes, K. R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btn663 · Cited by 61
Self-citationIntermolecular Interactions of the p85α Regulatory Subunit of Phosphatidylinositol 3-Kinase
Harpur, A. G., Layton, M. J., Das, P., Bottomley, M. J., Panayotou, G., Driscoll, P. C., & Waterfield, M. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.18.12323 · Cited by 57
Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma
Kang, S., Seo, S., Chang, H. J., Yoo, C. W., Park, S. Y., & Dong, S. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01172.x · Cited by 43
Characterization of the Met326Ile variant of phosphatidylinositol 3-kinase p85α
Almind, K., Delahaye, L., Hansen, T. F., OBBERGHEN, E. V., Pedersen, O. B., & Kahn, C. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042688799 · Cited by 35
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Metadata
- Authors
- Cheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke-Hale, K., Dyer, M. D., Zhang, F., Ju, Z., Cantley, L. C., Scherer, S. E., Liang, H., Lu, K. H., Broaddus, R. R., & Mills, G. B.
- Venue
- Cancer Discovery
- Published
- 2011-07-01
- Volume
- 1
- Issue
- 2
- Pages
- 170-185
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2167264978
- Cited by
- 470
- References
- 47
- FWCI
- 13.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.